Drug
Cosibelimab clinical trials
Keep track of what changes. Save the cosibelimab studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
- Cosibelimab
- 3
Studies by the year they started
4 studies that test it; most in 2017 (1)
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2019 | 1 |
| 2021 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 3 · Other 1
Checkpoint Therapeutics, Inc. (2) · Arsen Osipov (1) · TG Therapeutics, Inc. (1)
Often tested with
Tested in the same studies.
Related medicines
As reviewed, each with the page that says it.
- One of Immune Checkpoint Inhibitors source
- One of Immunologic Factors source
Studies
Open first, then newest update. How each study uses cosibelimab is read from its arms, and is right about nine times in ten.
Testing it · 4
- Phase I Study of Cosibelimab and Balixafortide in Metastatic Pancreatic Ductal AdenocarcinomaNot yet recruitingPhase 1Arsen OsipovNCT06981806Written as Cosibelimab
- Study of Pemetrexed+Platinum Chemotherapy With or Without Cosibelimab in First Line Metastatic Non-squamous NSCLCTerminatedPhase 3Checkpoint Therapeutics, Inc.NCT04786964Written as Cosibelimab
- Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced CancersActive, not recruitingPhase 1Checkpoint Therapeutics, Inc.NCT03212404Written as CK-301 (cosibelimab)
- Study of Cosibelimab in Subjects With Relapsed or Refractory LymphomaTerminatedPhase 1TG Therapeutics, Inc.NCT03778073Written as Cosibelimab
Given in every arm · 2 — cosibelimab is usual care beside what is tested
- Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic MalignancyRecruitingPhase 4Dana-Farber Cancer InstituteNCT07426484Written as Cosibelimab
- Study of Immunotherapy in Combination With Ublituximab and Umbralisib in Patients With Relapsed-refractory CLL or Richter's TransformationCompletedPhase 1TG Therapeutics, Inc.NCT02535286Written as TG-1501
Codes
What other systems call cosibelimab · ClinicalTrials.gg INT002103
- MeSH (NLM) C000731154cosibelimabOne source NLM
- UNII (FDA) PNW7GBB44PCOSIBELIMABConfirmed FDA, NLM
- NCI Thesaurus C151947CosibelimabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000731154 | cosibelimab | One source NLM |
| UNII (FDA) | PNW7GBB44P | COSIBELIMAB | Confirmed FDA, NLM |
| NCI Thesaurus | C151947 | Cosibelimab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.